Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
详细信息 查看全文
- 作者：Hui Zhang ; Yongan Yang ; Yifeng Wang ; Xinping Gao…
- 关键词：Ovarian cancer ; CA125 ; Tumor stem cell
- 刊名：Journal of Ovarian Research
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：8
- 期：1
- 全文大小：2,384 KB
- 参考文献：1. Borley, JWC, Brown, RGS (2012) Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer?. Syst Lit Rev 7: pp. 1069-74
2. Hamburger, AW (1977) SSE. Primary bioassay of human tumor stem cell. Science 197: pp. 461-3 CrossRef
3. Hui Zhang, XG, Yongan, Y (2014) New construction of an animal model for the orthotopic transplantation of an ovarian tumor. J Osvarian Res 7: pp. 64 CrossRef
4. Bon, GG, Kenemans, P, Verstraeten, R (1996) Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 174: pp. 107-14 CrossRef
5. Peters, WA (1986) CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract. Cancer 58: pp. 2625-7 CrossRef
6. Seidel, SBV (2010) A hypoxicnicle regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133: pp. 983-95 CrossRef
7. Hirohashi, YTT, Inoda, S (2010) Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunother 2: pp. 201-11 CrossRef
8. Ahmed, NAK, Findlay, J (2013) Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 114: pp. 21-34 CrossRef
9. Levanon, KNV, Piao, HY (2010) Primary ex-vivo cul-tures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29: pp. 1103-13 CrossRef
10. Levanon, KCC, Drapkin, R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: pp. 5284-93 CrossRef
11. Grasse·Gehling, PCC (2013) CD133 as a biomarker for putative cancer stem cells in solid tumours:limitations, problems and challenges. J Pathol 229: pp. 355-78 CrossRef
12. Muraro, MVS (2012) CD133+, CD166-?CD44+, and CD24+ CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell line. Stem Cells Transl Med 1: pp. 592-603 CrossRef
13. Lee, YW (2013) Nestin expresstion as an indicator of cervical cancer initiatior. Eur J Gynaecol Oncol Oncol 34: pp. 238-42
14. Jiang, FQQ, Khanna, A (2009) Aldehyde dehydrogenase 1is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: pp. 330-8 CrossRef
15. Wasaki, HS (2009) Cancer stem cells and their niche. Cancer Sci. 7: pp. 1166-72-6
16. Gupta, PBOTT, Jiang, G (2009) Idenification of selective inhibitons of cancer stem cell by high -throughput screening. Cell 138: pp. 546-659 CrossRef
17. Ishikawa, M, Yaginuma, Y, Hayashi, H, Shimizu, T, Endo, Y, Taniguchi, N (1990) Reactivity of a monoclonal antibody to manganese superoxide dismutase with human ovarian carcinoma. Cancer Res 50: pp. 2538-42
18. Bast, RC, Feeney, M, Lazarus, H, Nadler, LM, Colvin, RB, Knapp, RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: pp. 1331-7 CrossRef
19. Schummer, M, Drescher, C, Forrest, R, Gough, S, Thorpe, J, Hellstrom, I (2012) Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 125: pp. 65-9- 刊物主题：Gynecology; Reproductive Medicine;
- 出版者：BioMed Central
- ISSN：1757-2215
文摘
Purpose The purpose of this study is to identify a prospective association between CA125 and tumorigenic ovarian cancer cells, using the new method of orthotopic transplantation (1). Method After making the surgical ovarian cancer specimen into cell suspension, we separated the tumorigenic cells from the nontumorigenic cancer cells based on cell surface marker (cancer antigen CA125 and lineage markers) expression. We developed a SCID mice model in which the CA125+/ lineage- and CA125-/ lineage- cells were injected into ovarian parenchyma by use of a microinjector. As a measure of effectiveness of tumor-forming, tumor weight, abdominal distension, ascites volume and activity, subcutaneous fat were determined or observed. Immunohistochemistry was done to determine tumor cell markers. Results We found that the cells of CA125+/ lineage- were able to form new tumors; whereas, an equal quantity of CA125-/lineage- cells failed to form any tumors. The new generated tumor contained additional CA125-/lineage- tumorigenic cells as well as the phenotypically diverse population of nontumorigenic cells. Quantities were judged to be significantly different P--.0001. Conclusion CA125+/ lineage- cells, which may be ovarian cancer stem cells, were the source for tumor recurrence. The strategies designed to target this cell population may lead to more effective therapies.